138 related articles for article (PubMed ID: 38219810)
21. Substantial delays in clinical data published by the European Medicines Agency - a cross sectional study.
Paludan-Müller AS; Maclean-Nyegaard IR; Munkholm K
J Clin Epidemiol; 2022 Jun; 146():68-76. PubMed ID: 35292351
[TBL] [Abstract][Full Text] [Related]
22. Cross-comparison of cancer drug approvals at three international regulatory agencies.
Samuel N; Verma S
Curr Oncol; 2016 Oct; 23(5):e454-e460. PubMed ID: 27803605
[TBL] [Abstract][Full Text] [Related]
23. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
24. The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions.
De Wilde B; Barry E; Fox E; Karres D; Kieran M; Manlay J; Ludwinski D; Reaman G; Kearns P
J Clin Oncol; 2022 Oct; 40(29):3456. PubMed ID: 35947814
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
26. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
27. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors.
Hodkinson A; Dietz KC; Lefebvre C; Golder S; Jones M; Doshi P; Heneghan C; Jefferson T; Boutron I; Stewart L
Syst Rev; 2018 Aug; 7(1):117. PubMed ID: 30089508
[TBL] [Abstract][Full Text] [Related]
28. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports.
Schroll JB; Abdel-Sattar M; Bero L
J Clin Epidemiol; 2015 Jan; 68(1):102-7. PubMed ID: 25150193
[TBL] [Abstract][Full Text] [Related]
29. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of available studies and dissemination of research using major clinical data sharing platforms.
Vazquez E; Gouraud H; Naudet F; Gross CP; Krumholz HM; Ross JS; Wallach JD
Clin Trials; 2021 Dec; 18(6):657-666. PubMed ID: 34407656
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis.
Axson S; Mello MM; Lincow D; Yang C; Gross C; Ross JS; Miller J
BMJ Open; 2021 Jul; 11(7):e053248. PubMed ID: 34281933
[TBL] [Abstract][Full Text] [Related]
32. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages.
Hopkins AM; Modi ND; Abuhelwa AY; Kichenadasse G; Kuderer NM; Lyman GH; Wiese MD; McKinnon RA; Rockhold FW; Mann A; Rowland A; Sorich MJ
JAMA Oncol; 2023 Dec; 9(12):1621-1626. PubMed ID: 37796495
[TBL] [Abstract][Full Text] [Related]
34. EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets - a primer for academic researchers.
Sudlow R; Branson J; Friede T; Morgan D; Whately-Smith C
BMC Med Res Methodol; 2016 Jul; 16 Suppl 1(Suppl 1):73. PubMed ID: 27410386
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
[TBL] [Abstract][Full Text] [Related]
36. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.
Polak TB; van Rosmalen J; Uyl-de Groot CA
Br J Clin Pharmacol; 2020 Sep; 86(9):1819-1826. PubMed ID: 32200551
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
38. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance.
Bucci-Rechtweg C; Siapkara A; An Haack Bonnet K; Corriol Rohou S; Haf Davies E; Dehlinger Kremer M; Gamalo M; Moreno C; Nelson RM; Thomas Turner R
Clin Trials; 2023 Feb; 20(1):13-21. PubMed ID: 36341541
[TBL] [Abstract][Full Text] [Related]
39. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
40. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
